Article Data

  • Views 756
  • Dowloads 124

Original Research

Open Access

USP22 promotes the expression of GLUT1 and HK2 to facilitate growth and glycolysis in cervical cancer cells

  • Juan Xu1
  • Qingqing Tan1,*,
  • Ting Li2

1Department of Gynecological Oncology, Changzhou Maternal and Child Health Hospital affiliated to Nanjing Medical University, Changzhou City, Jiangsu Province, 213001, P. R. China

2Department of Pathology, Changzhou Maternal and Child Health Hospital affiliated to Nanjing Medical University, Changzhou City, Jiangsu Province, 213001, P. R. China

DOI: 10.31083/j.ejgo.2020.05.2158 Vol.41,Issue 5,October 2020 pp.790-796

Submitted: 22 October 2018 Accepted: 13 May 2019

Published: 15 October 2020

*Corresponding Author(s): Qingqing Tan E-mail: quyx78B@163.com

Abstract

Background: Cervical cancer is one of the most aggressive cancers in women, of which the pathogenesis should be further investigated to improve the prognosis. Objectives: The goal of this study is to investigate the role of ubiquitin-specific peptidase 22 (USP22) in cervical cancer and reveal its involvement in the signaling pathway. Results: Upregulation of USP22 was observed in cervical cancer tissues and cell lines. Cell proliferation, lactate production, glucose uptake and lactate dehydrogenase (LDH) activity was increased by overexpression of USP22 and decreased by suppression of USP22. The protein expression levels of Forkhead Box M1 (FoxM1), glucose transporter 1 (GLUT1) and hexokinase-2 (HK2) were upregulated by overexpression of USP22 and downregulated by suppression of USP22. Cotransfection of shUSP22 and FoxM1 attenuated the inhibitory effects of shUSP22 on the growth and glycolysis of cervical cancer cells. Conclusion: upregulation of USP22 in cervical cancer could promote cell proliferation and glycolysis through mediating FoxM1, indicating that USP22 and FoxM1 could be therapeutic targets in cervical cancer.


Keywords

USP22; GLUT1; HK2; Glycolysis; Cervical cancer cells.


Cite and Share

Juan Xu,Qingqing Tan,Ting Li. USP22 promotes the expression of GLUT1 and HK2 to facilitate growth and glycolysis in cervical cancer cells. European Journal of Gynaecological Oncology. 2020. 41(5);790-796.

References

[1] Bray F., Ferlay J., Soerjomataram I., Siegel R.L., Torre L.A., Jemal A.: “Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries”. CA: A Cancer Journal for Clinicians, 2018, 68, 394.

[2] Tota J.E., Bentley J., Blake J., Coutlée F., Duggan M.A., Ferenczy A., et al.: “Introduction of molecular HPV testing as the primary technology in cervical cancer screening: Acting on evidence to change the current paradigm”. Preventive Medicine, 2017, 98, 5.

[3] Kardum D., Filipović Grčić B., Muller A., Dessardo S.: “Outcomes of very low birth weight infants born by vaginal delivery versus cesarean section”. European Journal of Gynaecological Oncology: journal for intesive care and emergency medicine, 2018, 14, 46.

[4] Yadav N., Parveen S., Banerjee M.: “Potential of nano-phytochemicals in cervical cancer therapy”. Clinica Chimica Acta, 2020, 505, 60.

[5] Kalliala I., Athanasiou A., Veroniki A.A., Salanti G., Efthimiou O., Raftis N., et al.: “Incidence and mortality from cervical cancer and other malignancies after treatment of cervical intraepithelial neopla-sia: a systematic review and meta-analysis of the literature”. Annals of Oncology, 2020, 31, 213.

[6] Coronel J., Cantu D., Rodriguez-Morales M., Cetina L., González-Fierro A., Dueñas-González A.: “Carboplatin and low-dose paclitaxel. An effective regimen in older and comorbid patients with advanced cervical cancer. A phase II study”. Eur J Gynaecol Oncol, 2018, 39, 997.

[7] Fang J., Zhang H., Jin S.: “Epigenetics and cervical cancer: from pathogenesis to therapy”. Tumor Biology, 2014, 35, 5083.

[8] Clark K.L., Halay E.D., Lai E., Burley S.K.: “Cocrystal structure of the HNF-3/fork head DNA-recognition motif resembles histone H5”. Nature, 1993, 364, 412.

[9] Wierstra I.: “Chapter Six - FOXM1 (Forkhead box M1) in Tumori-genesis: Overexpression in Human Cancer, Implication in Tumori-genesis, Oncogenic Functions, Tumor-Suppressive Properties, and Target of Anticancer Therapy 􀀁􀀁 The present chapter is Part II of a two-part review on the transcription factor FOXM1. Part I of this FOXM1 review is published in Volume 118 of Advances in Cancer Research: Inken Wierstra. The Transcription Factor FOXM1 (Forkhead box M1): Proliferation-Specific Expression, Transcription Factor Function, Target Genes, Mouse Models, and Normal Biological Roles. Advances in Cancer Research, 2013, volume 118, pages 97–398”. In: Tew K.D., Fisher P.B., editors. Advances in Cancer Research: Academic Press; 2013. p. 191.

[10] Liao G.-B., Li X.-Z., Zeng S., Liu C., Yang S.-M., Yang L., et al.: “Regulation of the master regulator FOXM1 in cancer”. Cell communication and signaling : CCS, 2018, 16, 57.

[11] Chan D.W., Yu S.Y.M., Chiu P.M., Yao K.M., Liu V.W.S., Cheung A.N.Y., et al.: “Over-expression of FOXM1 transcription factor is associated with cervical cancer progression and pathogenesis”. The Journal of Pathology, 2008, 215, 245.

[12] Zhang X., Zhang L., Du Y., Zheng H., Zhang P., Sun Y., et al.: “A novel FOXM1 isoform, FOXM1D, promotes epithelial–mesenchymal transition and metastasis through ROCKs activation in colorectal cancer”. Oncogene, 2017, 36, 807.

[13] Melo-Cardenas J., Zhang Y., Zhang D.D., Fang D.: “Ubiquitin-specific peptidase 22 functions and its involvement in disease”. Oncotarget, 2016, 7, 44848.

[14] Jeusset L.M.P., McManus K.J.: “Ubiquitin Specific Peptidase 22 Regulates Histone H2B Mono-Ubiquitination and Exhibits Both Oncogenic and Tumor Suppressor Roles in Cancer”. Cancers, 2017, 9, 167.

[15] Ning Z., Wang A., Liang J., Xie Y., Liu J., Feng L., et al.: “USP22 promotes the G1/S phase transition by upregulating FoxM1 expres-sion via β-catenin nuclear localization and is associated with poor prognosis in stage II pancreatic ductal adenocarcinoma”. Int J Oncol, 2014, 45, 1594.

[16] Yang M., Liu Y.D., Wang Y.Y., Liu T.B., Ge T.T., Lou G.: “Ubiquitin-specific protease 22: a novel molecular biomarker in cervical cancer prognosis and therapeutics”. Tumour Biol, 2014, 35, 929.

[17] Ganapathy-Kanniappan S.: “Molecular intricacies of aerobic glycolysis in cancer: current insights into the classic metabolic phenotype”. Crit Rev Biochem Mol Biol, 2018, 53, 667.

[18] Deme D., Telekes A.: “[Prognostic importance of lactate dehydro-genase (LDH) in oncology]”. Orv Hetil, 2017, 158, 1977.

[19] Younes M., Lechago L.V., Somoano J.R., Mosharaf M., Lechago J.: “Wide expression of the human erythrocyte glucose transporter Glut1 in human cancers”. Cancer Res, 1996, 56, 1164.

[20] Yu M., Yongzhi H., Chen S., Luo X., Lin Y., Zhou Y., et al.: “The prognostic value of GLUT1 in cancers: a systematic review and meta-analysis”. Oncotarget, 2017, 8, 43356.

[21] Garcia S.N., Guedes R.C., Marques M.M.: “Unlocking the Potential of HK2 in Cancer Metabolism and Therapeutics”. Curr Med Chem, 2019, 26, 7285.

[22] Han B., Sun Y., Yang D., Zhang H., Mo S., Chen X., et al.: “USP22 promotes development of lung adenocarcinoma through ubiquitination and immunosuppression”. Aging (Albany NY), 2020, 12.

[23] Guan P., Chen H., Li H.J., Duan J., Chen J.Y.: “Expression and significance of FOXM1 in human cervical cancer: a tissue microarray study”. Clin Invest Med, 2011, 34, E1.


Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,500 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Biological Abstracts Easily discover critical journal coverage of the life sciences with Biological Abstracts, produced by the Web of Science Group, with topics ranging from botany to microbiology to pharmacology. Including BIOSIS indexing and MeSH terms, specialized indexing in Biological Abstracts helps you to discover more accurate, context-sensitive results.

Google Scholar Google Scholar is a freely accessible web search engine that indexes the full text or metadata of scholarly literature across an array of publishing formats and disciplines.

JournalSeek Genamics JournalSeek is the largest completely categorized database of freely available journal information available on the internet. The database presently contains 39226 titles. Journal information includes the description (aims and scope), journal abbreviation, journal homepage link, subject category and ISSN.

Current Contents - Clinical Medicine Current Contents - Clinical Medicine provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in clinical medicine.

BIOSIS Previews BIOSIS Previews is an English-language, bibliographic database service, with abstracts and citation indexing. It is part of Clarivate Analytics Web of Science suite. BIOSIS Previews indexes data from 1926 to the present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Submission Turnaround Time

Conferences

Top